16 47

Cited 1 times in

Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study

Authors
 Myung-Ju Ahn  ;  Igor Bondarenko  ;  Ewa Kalinka  ;  Byoung Chul Cho  ;  Shunichi Sugawara  ;  Gabriella Gálffy  ;  Byoung Yong Shim  ;  Nikolay Kislov  ;  Rajnish Nagarkar  ;  Ingel Demedts  ;  Steven J M Gans  ;  Dolores Mendoza Oliva  ;  Ross Stewart  ;  Zhongwu Lai  ;  Helen Mann  ;  Xiaojin Shi  ;  Maen Hussein 
Citation
 JOURNAL OF THORACIC ONCOLOGY, Vol.18(11) : 1594-1606, 2023-11 
Journal Title
JOURNAL OF THORACIC ONCOLOGY
ISSN
 1556-0864 
Issue Date
2023-11
MeSH
Antibodies, Monoclonal / adverse effects ; Antineoplastic Combined Chemotherapy Protocols* / adverse effects ; Humans ; Lung Neoplasms* / etiology ; Phthalazines / therapeutic use
Keywords
Durvalumab ; Immunotherapy ; NSCLC ; Olaparib ; PARP inhibition
Abstract
Introduction: Increased DNA damage triggered through poly (ADP-ribose) polymerase inhibition may modify tumor immunogenicity, sensitizing tumors to immunotherapy. ORION (NCT03775486) evaluated the combination of olaparib with durvalumab as maintenance therapy in patients with metastatic NSCLC.

Methods: ORION is a phase 2, randomized, multicenter, double-blind, international study. Patients with metastatic NSCLC (without activating EGFR or ALK aberrations) and Eastern Cooperative Oncology Group performance status of 0 or 1 were enrolled to receive initial therapy with durvalumab (1500 mg intravenously; every 3 wk) plus platinum-based chemotherapy for four cycles. Patients without disease progression were then randomized (1:1) to maintenance durvalumab (1500 mg; every 4 wk) plus either olaparib (300 mg orally) or placebo (both twice daily); randomization was stratified by objective response during initial therapy and tumor histologic type. The primary end point was investigator-assessed progression-free survival (PFS) (Response Evaluation Criteria in Solid Tumors version 1.1).

Results: Between January 2019 and February 2020, 269 of 401 patients who received initial therapy were randomized. As of January 11, 2021 (median follow-up: 9.6 mo), median PFS was 7.2 months (95% confidence interval: 5.3-7.9) with durvalumab plus olaparib versus 5.3 months (3.7-5.8) with durvalumab plus placebo (hazard ratio = 0.76, 95% confidence interval: 0.57-1.02, p = 0.074). Safety findings were consistent with the known profiles of durvalumab and olaparib. Anemia was the most common adverse event (AE) with durvalumab plus olaparib (26.1% versus 8.2% with durvalumab plus placebo). The incidence of grade 3 or 4 AEs (34.3% versus 17.9%) and AEs leading to treatment discontinuation (10.4% versus 4.5%) was numerically higher with durvalumab plus olaparib versus durvalumab plus placebo.

Conclusions: Maintenance therapy with durvalumab in combination with olaparib was not associated with a statistically significant improvement in PFS versus durvalumab alone, although numerical improvement was observed.
Files in This Item:
T202306442.pdf Download
DOI
10.1016/j.jtho.2023.06.013
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/196848
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links